VICAL INCORPORATED UNDERWRITING AGREEMENTUnderwriting Agreement • October 30th, 2017 • Vical Inc • Biological products, (no disgnostic substances) • New York
Vical Incorporated, a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of [●] shares of its common stock, par value $0.01 per share (the “Shares”). The [●] Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional [●] Shares as provided in Section 2. The additional [●] Shares to be sold by the Company pursuant to such option are collectively called the “Optional Shares.” The Firm Shares and, if and to the extent such option is exercised, the Optional Shares are collectively called the “Offered Shares.” H.C. Wainwright & Co., LLC (“HCW”) has agreed to act as representative of the several Underwriters, if any (in such capacity, the “Representative”), in connection with the offering and sale of the Offered Shares. To the extent there are no additional underwriters listed on Schedule A, the
